


Tryplase[®]

EXOCRINE PANCREATIC INSUFFICIENCY

TREATMENT WITH

Tryplase[®]

The treatment of choice



RESEARCH • PERFORMANCE • INTEGRITY

Exocrine Pancreatic Insufficiency (EPI)

Exocrine pancreatic insufficiency occurs in dogs and cats due to a progressive loss of the exocrine pancreatic acinar cells ultimately leading to an inadequate production of digestive enzymes. The most common cause of this condition in dogs is Pancreatic Acinar Atrophy (PAA). Although PAA may occur at any age in any breed, a high prevalence is recognised in young German Shepherds. The deficiency in pancreatic secretion results in maldigestion, nutrient malabsorption and osmotic diarrhoea. Once a diagnosis has been established most animals with EPI can be successfully managed by supplementing each meal with pancreatic enzymes.

EPI treatment with Tryplase

The main treatment for EPI is replacement of the pancreatic enzymes which the dog or cat can no longer produce naturally. Specifically formulated for dogs and cats, Tryplase contains the three major pancreatic enzymes responsible for digestion of fat, protein and starch in the small intestine.

The only licensed treatment for EPI


Tryplase is the only product licensed in the UK for the treatment of EPI. And whilst it is VMD authorised that's not the only good reason to choose Tryplase.

Effective – non-enteric coated, suited to the pet digestive tract

Some orally administered enzyme supplements are enteric-coated in an attempt to provide protection from gastric acid. While effective in humans their efficacy is variable in animals. A survey of dogs with EPI showed that enteric-coated preparations were often ineffective or less effective than non enteric-coated equivalents¹, possibly reflecting unreliable dissolution of the coating in the intestine or too rapid an intestinal transit before adequate enzyme release.

Tryplase is non enteric-coated so these problems are avoided.

The charts¹ below show the effect of preparation type on the response to enzyme replacement therapy. The results are expressed as a percentage of the dogs treated.



Convenient, accurate dosing in pre-measured capsules

Pre-measured capsules allow easy dosage measurement. Capsule contents are sprinkled directly on to the pet's food allowing easy administration and aiding long term owner compliance.



Low odour

Unlike some powders, the low odour formulation makes administration more pleasant.



Have you considered Tryplase for non-specific diarrhoea?

Tryplase is also useful where there is non-specific diarrhoea or persistent hypermotility of the intestine preventing adequate utilisation of pancreatic enzymes.


Administration and Dosage

Dogs

should have the contents of 2-5 capsules a day sprinkled on food (5 capsules are sufficient to digest the declared fat, protein and carbohydrate content of 1lb or 500g of dog food).


Cats

should have the contents of 1-2 capsules sprinkled on food each day (2 capsules are sufficient to digest the declared fat, protein and carbohydrate content of 1/2lb or 250g of cat food).



Tryplase's unique combination of benefits make it the treatment of choice for EPI:

- The only VMD authorised product licensed for treatment of EPI – the No.1 choice under veterinary medicine prescribing cascade
- Formulated specifically for replacement therapy or supplementation in dogs and cats
- Non-enteric coated preparation avoids enzyme release problems
- Pre-measured capsules facilitate accurate dosing and long term compliance
- Low odour makes administration more pleasant
- Also useful where there is non-specific diarrhoea or persistent hypermotility of the intestine





References

¹EJ Hall, PM Bond, C McLean, RM Batt and L McLean, A survey of the diagnosis and treatment of canine exocrine pancreatic insufficiency. Journal of Small Animal Practice (1991)

© Registered Trademark

Intervet UK Limited
 Walton Manor
 Walton
 Milton Keynes
 MK7 7AJ

For more information contact
 your Intervet Account Manager
 or call 01908 685 685

Item Code: 034654

61334+Dec2006/POL/10K



RESEARCH • PERFORMANCE • INTEGRITY